Alchemab Therapeutics
Cambridge, England, United Kingdom · Biotechnology, Health Care, Pharmaceutical
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled throug
Key facts
- Headquarters
- Cambridge, England, United Kingdom
- Employees
- 73
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Status
- Private
- Website
- alchemab.com
- Company page
Recent activity at Alchemab Therapeutics
- : Alchemab Therapeutics Appoints Dr Ben Porter-Brown as Chief Medical Officer
- : Alchemab extends its Series A funding round with £25m from British Business Bank, aimed at expanding its proprietary antibody database.
- : Alchemab Therapeutics Appoints Ulrich Wendt as Chief Business Officer
- : Alchemab Therapeutics raised an undisclosed amount in Series A extension financing, led by Ono Venture Investment along with existing investors. The funding will advance ATLX-2847 into clinical development.
- : Alchemab Therapeutics signs $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
- : Jane Osbourn Succeeds Young Kwon as CEO of Alchemab Therapeutics
- : Alchemab Raises £60M ($82M) In Series A Financing To Advance Novel Platform For Identifying Disease-Modifying Antibody Therapeutics
Alchemab Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Series A | $25.0M |
| Sep 2025 | Series A | Undisclosed |
| Apr 2021 | Series A | $60 |
Leadership
- Jorge Dias, Director Antibody Discovery
- Ben Porter-Brown, Chief Medical Officer
- Paul Varley, Chief Development Officer
- Ulrich Wendt, Chief Business Officer
- Donna Finch, Chief Operating Officer
- Olivia Cavlan, Chief Executive Officer
- Michelle Sidor, Scientist
- Brad Holub, Scientist and Manager
- Harry D., Senior Software Engineer
- Laura Mitchell, Bioinformatician
- Raul Tamas, Experience At Alchemab Therapeutics
- Jacob Galson, Not Provided
Verified email and direct lines for Alchemab Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Alchemab Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Alchemab Therapeutics in the news
- Alchemab Therapeutics Announces Largest Ever Life Sciences Investment From British Business Bank to Advance AI-Enabled Clinical Pipeline of Next Generation Human-Derived Antibodies - Business Wire (Jul 09, 2026)
- Ulrich Wendt joins UK biotech Alchemab Therapeutics as Chief Business Officer to expand biopharma partnerships - Business Wire (Mar 17, 2026)
- Alchemab Therapeutics Expands Leadership Team, Appointing Dr Ben Porter-Brown as CMO to Propel the Clinical Advancement of Its Pipeline - Yahoo Finance Australia (Sep 10, 2026)
- Alchemab Advances AI-Enabled Antibody Platform with Phase I Trial, $32 Million Financing Boost - Pharmaceutical Executive (Sep 09, 2025)
- Eli Lilly licenses early-stage ALS drug program from Alchemab in $415M pact - Fierce Biotech (May 06, 2025)
- Eli Lilly licensing AIchemab’s ALS antibody therapy in $415M deal - ALS News Today (May 13, 2025)
- Lilly Deepens ALS Pipeline With $415M Alchemab Licensing Deal - BioSpace (May 06, 2025)
- Lilly Bolsters ALS Pipeline Through $415 Million Licensing Agreement with Alchemab Therapeutics - Pharmaceutical Executive (May 06, 2025)
Companies similar to Alchemab Therapeutics
- Centessa Pharmaceuticals plc · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Biofrontera · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Abivax · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Santhera Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- TORL BioTherapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Alchemab Therapeutics: questions and answers
What does Alchemab Therapeutics do?
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled throug
Where is Alchemab Therapeutics headquartered?
Alchemab Therapeutics is headquartered in Cambridge, England, United Kingdom.
How many employees does Alchemab Therapeutics have?
Alchemab Therapeutics has about 73 employees.
Has Alchemab Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for Alchemab Therapeutics. The most recent, Series A of $25.0M, was in Jul 2026.
Who leads Alchemab Therapeutics?
Olivia Cavlan is a Chief Executive Officer at Alchemab Therapeutics.
What is the latest news on Alchemab Therapeutics?
On Sep 10, 2026, Alchemab Therapeutics Appoints Dr Ben Porter-Brown as Chief Medical Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy